Screener
Sarepta Therapeutics, Inc. SRPT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sarepta Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335003
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other comprehensive (loss) income | (444) | (85) | (837) | 167 |
| Comprehensive (loss) income | $(5,334) | $196,807 | $325,232 | $(250,449) |
| (Loss) earnings per share: | ||||
| Basic | $(0.05) | $2.01 | $3.10 | $(2.57) |
| Diluted | $(0.05) | $1.89 | $2.99 | $(2.57) |
| Weighted average number of shares of common stock used in computing (loss) earnings per share: | ||||
| Basic | 105,431 | 98,005 | 105,211 | 97,685 |
| Diluted | 105,431 | 106,623 | 122,260 | 97,685 |
Item 1. Financial Statements
FAQ
- What is Sarepta Therapeutics, Inc.'s EPS (diluted)?
- Sarepta Therapeutics, Inc. (SRPT) reported EPS (diluted) of -$0.05 in Q2 2026.
- How has Sarepta Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Sarepta Therapeutics, Inc.'s EPS (diluted) decreased by 102.6% year-over-year, from $1.89 to -$0.05.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Sarepta Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude